Literature DB >> 20132120

Effect of cocaine use on buprenorphine pharmacokinetics in humans.

Elinore F McCance-Katz1, Petrie M Rainey, David E Moody.   

Abstract

The effect of chronic cocaine use on buprenorphine pharmacokinetics was investigated to identify drug interactions and potential toxicities. In a retrospective analysis, pharmacokinetics were compared for 16 studies completed on subjects who were regular cocaine users and 74 studies on subjects who used cocaine only occasionally or not at all. All participants were stably maintained on buprenorphine/naloxone 16/4 mg daily. Participants who used cocaine regularly had lower buprenorphine exposure (AUC 34% lower; C(max) 27% lower and C(24) 37% lower; p <or= .001 for all comparisons). Regular cocaine users were younger (p = .0007), and used more heroin (p = .004) and cocaine (p < .0001). Regular cocaine use may result in lower buprenorphine plasma concentrations with potential for adverse clinical outcomes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20132120     DOI: 10.1111/j.1521-0391.2009.00001.x

Source DB:  PubMed          Journal:  Am J Addict        ISSN: 1055-0496


  9 in total

1.  Gender differences in pharmacokinetics of maintenance dosed buprenorphine.

Authors:  David E Moody; Wenfang B Fang; Jerdravee Morrison; Elinore McCance-Katz
Journal:  Drug Alcohol Depend       Date:  2011-04-23       Impact factor: 4.492

Review 2.  Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions.

Authors:  Robert Gharavi; William Hedrich; Hongbing Wang; Hazem E Hassan
Journal:  Pharm Res       Date:  2015-05-14       Impact factor: 4.200

3.  The impact of cocaine use on outcomes in HIV-infected patients receiving buprenorphine/naloxone.

Authors:  Lynn E Sullivan; Michael Botsko; Chinazo O Cunningham; Patrick G O'Connor; David Hersh; Jennifer Mitty; Paula J Lum; Richard S Schottenfeld; David A Fiellin
Journal:  J Acquir Immune Defic Syndr       Date:  2011-03-01       Impact factor: 3.731

4.  Evaluation of buprenorphine dosage adequacy in opioid receptor agonist substitution therapy for heroin dependence: first use of the BUprenorphine-naloxone Dosage Adequacy eVAluation (BUDAVA) questionnaire.

Authors:  Antonio D'Amore; Filomena Romano; Vincenzo Biancolillo; Guglielmo Lauro; Ciro Armenante; Anna Pizzirusso; Salvatore Del Tufo; Ciro Ruoppolo; Francesco Auriemma; Francesco Cassese; Patrizia Oliva; Patrizia Amato
Journal:  Clin Drug Investig       Date:  2012-07-01       Impact factor: 2.859

Review 5.  Drug interactions associated with methadone, buprenorphine, cocaine, and HIV medications: implications for pregnant women.

Authors:  Elinore F McCance-Katz
Journal:  Life Sci       Date:  2010-10-19       Impact factor: 5.037

6.  Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients.

Authors:  Elinore F McCance-Katz; David E Moody; Sudha Prathikanti; Gerald Friedland; Petrie M Rainey
Journal:  Drug Alcohol Depend       Date:  2011-05-19       Impact factor: 4.492

7.  Computational Systems Pharmacology-Target Mapping for Fentanyl-Laced Cocaine Overdose.

Authors:  Jin Cheng; Siyi Wang; Weiwei Lin; Nan Wu; Yuanqiang Wang; Maozi Chen; Xiang-Qun Xie; Zhiwei Feng
Journal:  ACS Chem Neurosci       Date:  2019-07-15       Impact factor: 4.418

8.  The association between cocaine use and treatment outcomes in patients receiving office-based buprenorphine/naloxone for the treatment of opioid dependence.

Authors:  Lynn E Sullivan; Brent A Moore; Patrick G O'Connor; Declan T Barry; Marek C Chawarski; Richard S Schottenfeld; David A Fiellin
Journal:  Am J Addict       Date:  2010 Jan-Feb

Review 9.  Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review.

Authors:  Elinore F McCance-Katz; Lynn E Sullivan; Srikanth Nallani
Journal:  Am J Addict       Date:  2010 Jan-Feb
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.